ArticleConsider this SGLT2 inhibitor for patients with HF with preserved ejection fractionAuthor:Gregory Castelli, PharmD, BCPS, BC-ADM, CDCESPublish date: December 19, 2022The addition of empagliflozin to usual therapy reduced hospitalization risk, regardless of patients’ diabetes status.Read More
